Imugene says 2021 has been stellar year so far as it rapidly advances anti-cancer programs
proactiveinvestors.com.au - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com.au Daily Mail and Mail on Sunday newspapers.
BioInvent s partner Oncurious NV presents Phase I data on TB-403 in pediatric cancer
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Instil Bio Presents Clinical Data in Metastatic Melanoma in a Late-Breaking e-Poster at the .
Instil BioApril 12, 2021 GMT
67% overall response rate and 19% complete response rate in 21 patients
All complete responders remained in remission at time of data cut-off
DALLAS, April 12, 2021 (GLOBE NEWSWIRE) Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, presented clinical data from a compassionate use program for the treatment of metastatic melanoma at the American Association for Cancer Research (AACR) virtual meeting April 10 – 15, 2021. The presentation abstract and additional information is available on the AACR conference web site at www.aacr.org.